TOMI Environmental Solutions (TOMZ) Q4 2025 earnings summary

Executive summary

• Achieved first commercial installation of SteraMist Integrated System (SIS) and expanded to four operational enclosures by year-end 2025.

• Secured major contracts and partnerships in biopharma, cell/gene therapy, NASA, Total Clean Air, and expanded into agriculture, food safety, and university research sectors.

• Expanded SteraMist iHP applications in food safety, driven by favorable FDA regulatory developments.

• Built recurring revenue streams through open monthly bid solutions, OEM partnerships, and international regulatory approvals.

• Maintained strong industry recognition, winning Disinfection Decontamination Products Company of the Year 2025.

Financial highlights

• 2025 revenue was $5.64 million, down from $7.74 million in 2024, mainly due to deferred customer capital expenditures amid economic uncertainty and tariffs.

• Gross margin improved to approximately 55% from 46% year-over-year.

• Operating expenses decreased by about 10% to $6.9 million.

• Net loss narrowed to $3.75 million ($0.19/share) from $4.48 million ($0.22/share) in 2024.

• Ended 2025 with $88,000 in cash and $1 million in working capital.

Outlook and guidance

• Projected 2026 revenue of $12 million, with Q1 2026 revenue already exceeding Q1 2025.

• Recurring revenue streams and backlog for support services and BIT Solution up 16% and 24% respectively in Q1 2026 year-over-year.

• Integration project pipeline at $16 million and SteraMist iHP opportunity book at $20 million.

• Management expects resumed customer activity as deferred projects normalize and anticipates continued international expansion and recurring revenue growth.

• Focused on trends in clean manufacturing, AI-enabled automation, and biosecurity.